CAR-T Cell Therapy Market to Register Healthy Growth through 2025
Increasing prevalence of
cancer and widespread research activities to drive global CAR-T cell therapy
market
According to
TechSci Research report, “Global CAR-T
Cell Therapy Market By Indication (Diffused Large B-cell Lymphoma (DLBCL),
Acute Lymphoblastic Leukemia (ALL), Multiple Myeloma (MM), Chronic Lymphocytic
Leukemia (CLL), Follicular Lymphoma (FL), Others), By Targeted Antigen(CD 19,
CD22, BCMA (B-Cell Maturation Antigen), HER1, HER2, Meso, EGFRvlll, Others), By
Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel),
JCAR017 (Lisocabtagene Maraleucel), bb2121), By End User (Hospitals, Cancer
Treatment Centers, Others), By Region, Forecast & Opportunities, 2025”, the market is anticipated to grow at a robust CAGR during
the forecast period. Key factors fueling the growth of global CAR-T cell
therapy market include rising prevalence of cancer around the globe and
increasing need for breakthrough therapeutic solutions. There is an increasing
number of patients who are showing response failure to alternative treatments.
This factor is also expected to foster the growth of global CAR-T cell therapy
market in the coming years. Moreover, rising R&D expenditure and boom in the
field of immuno-oncology are some other factors propelling the growth of this
market. Also, rising government initiatives for promoting research for cell
therapy in cancer and improving health care infrastructure are supporting the
growth of global CAR-T cell therapy market.
Additionally, increasing clinical trials and development
of new and effective therapy options are driving the growth of this market. The
effectiveness of CAR-T cell therapy in treating cancer is anticipated to
present huge growth opportunities for pharmaceutical and biotech companies.
However, the market might also face some restrains. The complicated manufacturing
process of CAR-T cells and high cost of the treatment might hamper the market
growth. Furthermore, side effects of CAR-T cell therapy may lead to
neurological problems and cytokine release syndrome (CRS). This factor also might
pose as a challenge for the growth of global CAR-T cell therapy market.
Browse XX market data Tables and XX Figures spread through XXX Pages and an in-depth TOC on "Global CAR-T Cell Therapy Market"
https://www.techsciresearch.com/report/car-t-cell-therapy-market/5168.html
The global CAR-T
cell therapy market is segmented based on indication, targeted antigen, product
type, end user and region. Based on targeted antigen, the market can be
segmented into CD 19, CD22, BCMA (B-Cell Maturation Antigen), HER1, HER2, Meso,
EGFRvlll and others. Among them, CD 19 antigen is expected to hold largest
market share during the forecast period as more companies are able to get their
CD 19 antigens approved and have them commercialized. However, B-Cell
Maturation Antigen (BCMA) is anticipated to witness fastest CAGR through 2025
as they play a critical role in regulating B-cell proliferation and survival.
Based on
indication, global CAR-T cell therapy market can be segmented into Diffused
Large B-cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Multiple
Myeloma (MM), Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma (FL) and
others. Among them, Diffused Large B-cell Lymphoma (DLBCL) segment is expected
to witness high growth during the forecast period as it is one of the most
common types of non-Hodgkin lymphoma around the world.
Major players operating in the global
CAR-T cell therapy market include Kite Pharma (subsidiary of Gilead Sciences),
AbbVie Inc., Bluebird Bio, Bristol Myers Squibb (BMS), Gilead Sciences, Inc.,
Cellectis, Servier Laboratories, Pfizer Inc., Merck KGaA, Juno Therapeutics,
Amgen Inc., Intellia Therapeutics, Novartis International AG, Caribou
Biosciences, Inc., Celyad, Bellicum Pharmaceuticals, Inc., Noile-Immune
Biotech, Cartesian Therapeutics, Johnson & Johnson and Sangamo
Therapeutics, Inc. The companies are undergoing extensive research & development
activities to launch new targeted cell therapies in the market.
Download
Sample Report @
https://www.techsciresearch.com/sample-report.aspx?cid=5168
Customers can
also request for 10% free customization on this report.
“North America
dominated the global CAR-T cell therapy market in 2019 and is expected to hold
its dominance through 2025 owing to large patient pool suffering from cancer in
countries such as United States and Canada. Also, rapid development and launch
of new therapies for the treatment of cancer by leading companies is making the
region a profitable market for manufactures. Following North America, Europe is
anticipated to be the second most prominent market for CAR-T cell therapy due
to extensive research for development of cancer therapies in the region,” said
Mr. Karan Chechi, Research Director with TechSci Research, a research based
global management consulting firm.
“Global CAR-T Cell Therapy Market By Indication
(Diffused Large B-cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL),
Multiple Myeloma (MM), Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma
(FL), Others), By Targeted Antigen(CD 19, CD22, BCMA (B-Cell Maturation
Antigen), HER1, HER2, Meso, EGFRvlll, Others), By Product Type (Yescarta
(Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), JCAR017 (Lisocabtagene
Maraleucel), bb2121), By End User (Hospitals, Cancer Treatment Centers, Others),
By Region, Forecast & Opportunities, 2025” has evaluated the future growth potential of global CAR-T cell therapy market
and provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges and opportunities in global CAR-T cell therapy market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]